# EDGAR Filing Document

**Accession Number:** 0001122411
**File Stem:** 0000950103-26-005722
**Filing Date:** 2026-4
**Character Count:** 29945
**Document Hash:** 000970064c987c21aab0a612235dc3b1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950103-26-005722.hdr.sgml**: 20260416

**ACCESSION NUMBER**: 0000950103-26-005722

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20260415

**DATE AS OF CHANGE**: 20260415

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ainos, Inc.
- **CENTRAL INDEX KEY:** 0001014763
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 751974352
- **STATE OF INCORPORATION:** TX
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-46755
- **FILM NUMBER:** 26862471

**BUSINESS ADDRESS:**
- **STREET 1:** 3050 POST OAK BLVD,
- **STREET 2:** SUITE 510-T80
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77056
- **BUSINESS PHONE:** (281) 898-6586

**MAIL ADDRESS:**
- **STREET 1:** 3050 POST OAK BLVD,
- **STREET 2:** SUITE 510-T80
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77056

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AMARILLO BIOSCIENCES INC
- **DATE OF NAME CHANGE:** 19960516
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ASE Technology Holding Co., Ltd.
- **CENTRAL INDEX KEY:** 0001122411
- **STANDARD INDUSTRIAL CLASSIFICATION:** SEMICONDUCTORS & RELATED DEVICES [3674]
- **ORGANIZATION NAME:** 04 Manufacturing
- **EIN:** 000000000
- **STATE OF INCORPORATION:** F5
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 26, CHIN 3RD RD.
- **STREET 2:** NANZIH DISTRICT
- **CITY:** KAOHSIUNG
- **PROVINCE COUNTRY:** F5
- **ZIP:** 811
- **BUSINESS PHONE:** 886-7-361-7173

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 26, CHIN 3RD RD.
- **STREET 2:** NANZIH DISTRICT
- **CITY:** KAOHSIUNG
- **PROVINCE COUNTRY:** F5
- **ZIP:** 811

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ASE Industrial Holding Co., Ltd.
- **DATE OF NAME CHANGE:** 20180430

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ADVANCED SEMICONDUCTOR ENGINEERING INC
- **DATE OF NAME CHANGE:** 20000822

## Ex-1

**EXHIBIT 1**

**JOINT FILING AGREEMENT**

In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including any amendments thereto) with respect to the Common Stock of Ainos, Inc. and further agree that this Agreement be included as an exhibit to such joint filing.

This Agreement may be executed in counterparts, each of which will be deemed an original, but all of which together shall constitute one and the same instrument.

The undersigned, being duly authorized, hereby execute this Agreement April 15, 2026.

**ASE TECHNOLOGY HOLDING CO., LTD.**<br>By: <u>/s/ Joseph Tung</u>___________<br>Name: Joseph Tung<br>Title: Chief Financial Officer<br>**ASE TEST, INC.** <br>By: <u>/s/ Alan Li</u>________________<br>Name: Alan Li<br>Title: Director<br>

## Ex-99.A

**Exhibit 99.A**

**Schedule A**

**Directors and Executive Officers of ASE Technology Holding Co., Ltd.**

---

| | | | |
|:---|:---|:---|:---|
| **Name of director**<br>**or executive officer**<br>| **Residence** <br> **or business address**<br>| **Present principal occupation** <br> **or employment**  | **Nationality** |
| Jason C.S. Chang | 26, Chin 3rd Rd.,<br>Nanzih Dist.,<br>Kaohsiung, 811, Taiwan<br>Republic of China<br>| Director and Chairman | Singapore |
| Richard H.P. Chang | 26, Chin 3rd Rd.,<br>Nanzih Dist.,<br>Kaohsiung, 811, Taiwan<br>Republic of China<br>| Director, Vice Chairman and President | Hong Kong |
| Tien Wu | 26, Chin 3rd Rd.,<br>Nanzih Dist.,<br>Kaohsiung, 811, Taiwan<br>Republic of China<br>| Director and Chief Operating Officer | Taiwan |
| Jeffrey Chen | 26, Chin 3rd Rd.,<br>Nanzih Dist.,<br>Kaohsiung, 811, Taiwan<br>Republic of China<br>| Director; Chairman, Universal Scientific Industrial (Shanghai) Co., Ltd. | Taiwan |
| Andrew Tang | 26, Chin 3rd Rd.,<br>Nanzih Dist.,<br>Kaohsiung, 811, Taiwan<br>Republic of China<br>| Director; Chief Procurement Officer; Vice Chairman, Advanced Semiconductor Engineering Inc. | United States |
| Dan-Yao Chang | 26, Chin 3rd Rd.,<br>Nanzih Dist.,<br>Kaohsiung, 811, Taiwan<br>Republic of China<br>| Director and Special Assistant to Chairman | United States |
| Shen-Fu Yu | 26, Chin 3rd Rd.,<br>Nanzih Dist.,<br>Kaohsiung, 811, Taiwan<br>Republic of China<br>| Independent Director and Member of Audit Committee, Compensation Committee, Risk Management Committee, and Corporate Sustainability and Information Security Committee | Taiwan |
| Mei-Yueh Ho | 26, Chin 3rd Rd.,<br>Nanzih Dist.,<br>Kaohsiung, 811, Taiwan<br>Republic of China<br>| Independent Director and Member of Audit Committee, Risk Management Committee, and Corporate Sustainability and Information Security Committee | Taiwan |
| Wen-Chyi Ong | 26, Chin 3rd Rd.,<br>Nanzih Dist.,<br>Kaohsiung, 811, Taiwan<br>Republic of China<br>| Independent Director and Member of Audit Committee, Compensation Committee, and Corporate Sustainability and Information Security Committee | Taiwan |
| Chi-Wen Tsai | 26, Chin 3rd Rd.,<br>Nanzih Dist.,<br>Kaohsiung, 811, Taiwan<br>Republic of China<br>| Chairman and President, Siliconware Precision Industries Co., Ltd. | Taiwan |
| Joseph Tung | Room 1901, No. 333, Section 1 Keelung Rd.<br>Taipei, 110, Taiwan,<br>Republic of China<br>| Chief Financial Officer | Taiwan |

---

---

| | | | |
|:---|:---|:---|:---|
| **Name of director**<br>**or executive officer**<br>| **Residence** <br> **or business address**<br>| **Present principal occupation** <br> **or employment**  | **Nationality** |

---

---

| | | | |
|:---|:---|:---|:---|
| Raymond Lo | 26, Chin 3rd Rd.,<br>Nanzih Dist.,<br>Kaohsiung, 811, Taiwan<br>Republic of China<br>| General Manager, ASE Test Taiwan and Kaohsiung packaging facility | Taiwan |
| Tien-Szu Chen | 26, Chin 3rd Rd.,<br>Nanzih Dist.,<br>Kaohsiung, 811, Taiwan<br>Republic of China<br>| General Manager, Advanced Semiconductor Engineering Inc. Chung-Li branch | Taiwan |
| Du-Tsuen Uang | 26, Chin 3rd Rd.,<br>Nanzih Dist.,<br>Kaohsiung, 811, Taiwan<br>Republic of China<br>| Chief Administration Officer | Taiwan |
| Chung Lin | 26, Chin 3rd Rd.,<br>Nanzih Dist.,<br>Kaohsiung, 811, Taiwan<br>Republic of China<br>| General Manager, ASE (Shanghai) Inc. and ASE Electronics Inc.<br>| Taiwan |
| Gichol Lee | 26, Chin 3rd Rd.,<br>Nanzih Dist.,<br>Kaohsiung, 811, Taiwan<br>Republic of China<br>| General Manager, ASE (Korea) Inc. | United States |
| Chih-Hsiao Chung | 26, Chin 3rd Rd.,<br>Nanzih Dist.,<br>Kaohsiung, 811, Taiwan<br>Republic of China<br>| General Manager, ASE Japan Co. Ltd. and Wuxi Tongzhi Microelectronics Co., Ltd. | Taiwan |
| Kwai Mun Lee | 26, Chin 3rd Rd.,<br>Nanzih Dist.,<br>Kaohsiung, 811, Taiwan<br>Republic of China<br>| President, ASE South-East Asia operations | Singapore |
| Yean Peng Chen | 26, Chin 3rd Rd.,<br>Nanzih Dist.,<br>Kaohsiung, 811, Taiwan<br>Republic of China<br>| General Manager, ASE Singapore Pte. Ltd. | Singapore |
| Kelvin Fook Lin Liu | 26, Chin 3rd Rd.,<br>Nanzih Dist.,<br>Kaohsiung, 811, Taiwan<br>Republic of China<br>| General Manager, ASE Electronics (M) Sdn. Bhd. | Malaysia |
| Kenneth Hsiang | 26, Chin 3rd Rd.,<br>Nanzih Dist.,<br>Kaohsiung, 811, Taiwan<br>Republic of China<br>| Chief Executive Officer, ISE Labs, Inc. | United States |
| Kevin Yu | 26, Chin 3rd Rd.,<br>Nanzih Dist.,<br>Kaohsiung, 811, Taiwan<br>Republic of China<br>| General Manager, Siliconware Technology (Suzhou) Limited | Taiwan |
| Chen-Yen Wei | 26, Chin 3rd Rd.,<br>Nanzih Dist.,<br>Kaohsiung, 811, Taiwan<br>Republic of China<br>| Chairman, Universal Scientific Industrial Co., Ltd.; President, Universal Scientific Industrial (Shanghai) Co., Ltd.; General Manager, Universal Global Scientific Industrial Co., Ltd.<br>| Taiwan<br>|

---

---

| | | | |
|:---|:---|:---|:---|
| **Name of director**<br>**or executive officer**<br>| **Residence** <br> **or business address**<br>| **Present principal occupation** <br> **or employment**  | **Nationality** |

---

---

| | | | |
|:---|:---|:---|:---|
| Ta-I Lin | 26, Chin 3rd Rd.,<br>Nanzih Dist.,<br>Kaohsiung, 811, Taiwan<br>Republic of China<br>| General Manager, Universal Global Technology (Kunshan) Co. Ltd. and<br>Universal Global Technology (Huizhou) Co., Ltd.<br>| Taiwan |
| Hui-Min Liu | 26, Chin 3rd Rd.,<br>Nanzih Dist.,<br>Kaohsiung, 811, Taiwan<br>Republic of China<br>| General Manager, UNIVERSAL SCIENTIFIC INDUSTRIAL VIETNAM COMPANY LIMITED | Taiwan |
| Tuck Weng Lee | 26, Chin 3rd Rd.,<br>Nanzih Dist.,<br>Kaohsiung, 811, Taiwan<br>Republic of China<br>| General Manager, Universal Scientific Industrial De Mexico S.A. De C.V. | Singapore |
| Nicolas Denis | 26, Chin 3rd Rd.,<br>Nanzih Dist.,<br>Kaohsiung, 811, Taiwan<br>Republic of China<br>| Chief Executive Officer, Financière AFG | France |
| Ying Pin Wu | 26, Chin 3rd Rd.,<br>Nanzih Dist.,<br>Kaohsiung, 811, Taiwan<br>Republic of China<br>| General Manager, Asteelflash Suzhou Co., Ltd. | United States |
| Dirk Wendt | 26, Chin 3rd Rd.,<br>Nanzih Dist.,<br>Kaohsiung, 811, Taiwan<br>Republic of China<br>| General Manager, HCC Group | Germany |
| Yee Voon Hew | 26, Chin 3rd Rd.,<br>Nanzih Dist.,<br>Kaohsiung, 811, Taiwan<br>Republic of China<br>| General Manager, ASE Cheonan, Inc. | Malaysia |
| Meng-Hui Lin | 26, Chin 3rd Rd.,<br>Nanzih Dist.,<br>Kaohsiung, 811, Taiwan<br>Republic of China<br>| General Manager, Universal Global Technology (Shanghai) Co., Ltd | Taiwan |

---

Directors and Executive Officers of ASE Test Taiwan

---

| | | | |
|:---|:---|:---|:---|
| **Name of director**<br>**or executive officer**<br>| **Residence** <br> **or business address**<br>| **Present principal occupation** <br> **or employment**  | **Nationality** |
| Jason C.S. Chang | 10, West 5th Street, Nanzih Dist., Kaohsiung, 811, Taiwan | Director and Chairman | Singapore |
| Dan Yao Chang | 10, West 5th Street, Nanzih Dist., Kaohsiung, 811, Taiwan | Director | United States |
| Raymond Lo | 10, West 5th Street, Nanzih Dist., Kaohsiung, 811, Taiwan | Director; General Manager, ASE Test Taiwan and Kaohsiung packaging facility | Taiwan |
| Tien-Szu Chen | 10, West 5th Street, Nanzih Dist., Kaohsiung, 811, Taiwan | Director; General Manager, Advanced Semiconductor Engineering Inc. Chung-Li branch | Taiwan |
| Jeffrey Chen | 10, West 5th Street, Nanzih Dist., Kaohsiung, 811, Taiwan | Director; Chairman, Universal Scientific Industrial (Shanghai) Co., Ltd. | Taiwan |
| Shih Hua Pan | 10, West 5th Street, Nanzih Dist., Kaohsiung, 811, Taiwan | Director | Taiwan |
| Chun Che Lee | 10, West 5th Street, Nanzih Dist., Kaohsiung, 811, Taiwan | Director | Taiwan |
| Jerry Chang | 10, West 5th Street, Nanzih Dist., Kaohsiung, 811, Taiwan | Director<br>| United Kingdom |
| Alan Li | 10, West 5th Street, Nanzih Dist., Kaohsiung, 811, Taiwan | Director | Taiwan |
| Alan Cheng | 10, West 5th Street, Nanzih Dist., Kaohsiung, 811, Taiwan | Director | Taiwan |
| Anne Chang | 10, West 5th Street, Nanzih Dist., Kaohsiung, 811, Taiwan | Director | Taiwan |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 2)**

**Ainos, Inc.**

*(Name of Issuer)*

**Common Stock, par value $0.01 per share**

*(Title of Class of Securities)*

**—**

*(CUSIP Number)*

**Joseph Tung**<br>ROOM 1901, NO. 333, SECTION 1 KEELUNG RD<br>Taipei F5 110<br>886266365678

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**04/12/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**ASE Technology Holding Co., Ltd.** | Name of reporting person<br>**ASE Technology Holding Co., Ltd.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**F5** | Citizenship or place of organization<br>**F5** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**667085.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**667085.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**667085.00** | Aggregate amount beneficially owned by each reporting person<br>**667085.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**8.4%** | Percent of class represented by amount in Row (11)<br>**8.4%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Comment for Reporting Person:** Note to Rows 8, 10, and 11: Represents beneficial ownership of 667,085 shares of Common Stock, $0.01 par value (the "Common Stock"), of Ainos, Inc., a Texas corporation (the "Issuer"), after giving effect to the one-for-five reverse stock split of the Issuer's common stock effected on June 30, 2025 (the "June 2025 Reverse Split"), consisting of the following: (i) 11,777 shares owned directly by ASE Test Taiwan (as defined below); (ii) 105,868 shares pursuant to the 2023 Agreement (as defined below) between ASE Test Taiwan and the Issuer, as amended by the 2023 Agreement Amendment (as defined below); (iii) 449,440 shares of common stock pursuant to the 2024 Agreement (as defined below) between ASE Test Taiwan and the Issuer; and (iv) 100,000 shares that ASE Test Taiwan can obtain by conversion of a warrant it holds that was issued under the 2024 Agreement. For the purposes of these calculations, the number of shares convertible under the 2023 Agreement, as amended by the 2023 Agreement Amendment, and under the 2024 Agreement, is calculated based on a conversion price of $22.50 per share. This conversion price represents the maximum potential number of shares ASE Test Taiwan could receive upon conversion. For further details, please see Item 3 and Item 6.

Note to Row 13: Based on the sum of (i) 7,266,011 shares of common stock outstanding as of March 30, 2026 as set forth in the annual report on Form 10-K of the Issuer filed with the SEC on March 30, 2026 (ii) 105,868 shares of common stock convertible pursuant to the 2023 Agreement (as defined below) as amended and modified by the 2023 Agreement Amendment (as defined below) (iii) 449,440 shares of common stock convertible pursuant to the 2024 Agreement (as defined below) and (iv) 100,000 shares of common stock convertible upon the exercise of the warrant ASE Test Taiwan obtained as part of the 2024 Agreement.

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**ASE Test, Inc.** | Name of reporting person<br>**ASE Test, Inc.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**F5** | Citizenship or place of organization<br>**F5** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**667085.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**667085.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**667085.00** | Aggregate amount beneficially owned by each reporting person<br>**667085.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**8.4%** | Percent of class represented by amount in Row (11)<br>**8.4%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Comment for Reporting Person:** Note to Rows 8, 10, and 11: Represents beneficial ownership of 667,085 shares of Common Stock, $0.01 par value (the "Common Stock"), of Ainos, Inc., a Texas corporation (the "Issuer"), after giving effect to the one-for-five reverse stock split of the Issuer's common stock effected on June 30, 2025 (the "June 2025 Reverse Split"), consisting of the following: (i) 11,777 shares owned directly by ASE Test Taiwan (as defined below); (ii) 105,868 shares pursuant to the 2023 Agreement (as defined below) between ASE Test Taiwan and the Issuer, as amended by the 2023 Agreement Amendment (as defined below); (iii) 449,440 shares of common stock pursuant to the 2024 Agreement (as defined below) between ASE Test Taiwan and the Issuer; and (iv) 100,000 shares that ASE Test Taiwan can obtain by conversion of a warrant it holds that was issued under the 2024 Agreement. For the purposes of these calculations, the number of shares convertible under the 2023 Agreement, as amended by the 2023 Agreement Amendment, and under the 2024 Agreement, is calculated based on a conversion price of $22.50 per share. This conversion price represents the maximum potential number of shares ASE Test Taiwan could receive upon conversion. For further details, please see Item 3 and Item 6.

Note to Row 13: Based on the sum of (i) 7,266,011 shares of common stock outstanding as of March 30, 2026 as set forth in the Annual Report on Form 10-K of the Issuer filed with the SEC on March 30, 2026 (ii) 105,868 shares of common stock convertible pursuant to the 2023 Agreement (as defined below) as amended and modified by the 2023 Agreement Amendment (as defined below) (iii) 449,440 shares of common stock convertible pursuant to the 2024 Agreement (as defined below) and (iv) 100,000 shares of common stock convertible upon the exercise of the warrant ASE Test Taiwan obtained as part of the 2024 Agreement.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.01 per share

**(b) Name of Issuer:**
Ainos, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
3050 POST OAK BLVD,, SUITE 510-T80, Houston, TX, 77056

This Schedule 13D amendment is being filed to reflect the accrual of interest pursuant to the Convertible Promissory Note Purchase Agreement the Issuer entered into with ASE Test Taiwan (as defined below) on March 13, 2023 (the "2023 Agreement") according to which ASE Test Taiwan committed to pay a total aggregate amount of $2,000,000 to the Issuer in exchange for convertible promissory note(s). The 2023 Agreement has been amended by a supplementary agreement entered into between the Issuer and ASE Test Taiwan on March 10, 2025 (the "2023 Agreement Amendment"). The note bears 6% compound interest and matures on March 12, 2027. The note will be convertible into shares of Common Stock at a conversion price equal to the lower of (a) $37.50 per share and (b) the higher of (x) the average closing price per share for the period of thirty (30) trading days prior to the day when ASE Test Taiwan exercises the conversion right or (y) $22.50 per share (or 105,868 shares), subject to anti-dilutive adjustment as set forth in the note. This Schedule 13D amendment is also being filed to reflect the accrual of interest pursuant to the Convertible Note and Warrant Purchase Agreement the Issuer entered into with ASE Test Taiwan (as defined below) on May 3, 2024 (the "2024 Agreement"), according to which ASE Test Taiwan committed to pay a total aggregate amount of $9,000,000 to the Issuer in exchange for convertible note(s). The note bears 6% compound interest and matures on May 15, 2027. The note bears 6% compound interest and has a three-year term. The note will be convertible into shares of Common Stock at a conversion price of $22.50 per share (or 449,440 shares), subject to customary anti-dilution adjustments.

This statement on Schedule 13D (this "Statement") relates to the Common Stock, par value $0.01 per share of the Issuer. The address of the principal executive corporate offices of the Issuer is 3050 Post Oak Blvd, Suite 510-T80, Houston, TX 77056.

**Item 4. Purpose of Transaction**

The purpose of the acquisition was to make a financial investment in the Issuer.

The Reporting Persons may engage in discussions with management, the board of directors of the Issuer (the "Board"), other shareholders of the Issuer and other relevant parties concerning the business, assets, capitalization, financial condition, operations, management, strategy, potential business combinations and strategic alternatives, and future plans of the Issuer. The Reporting Persons also may consider, formulate, discuss and seek to cause the Issuer to implement various plans or proposals intended to protect, preserve or enhance stockholder value or protect, preserve or enhance the value of the Issuer's assets, including plans or proposals that may involve extraordinary matters relating to the Issuer. Any such actions or transactions may be taken, advocated by, or involve the Reporting Persons alone or in conjunction with other shareholders, financing sources and/or other third parties, and could include proposing or considering one or more of the actions described in subsections (a) through (j) of Item 4 of Schedule 13D.

The Reporting Persons intend to review their investments in the Issuer on a continuing basis. Depending on various factors, including, without limitation, the Issuer's financial position and strategic direction, actions taken by the Board, price levels of shares of the Common Stock, other investment opportunities available to the Reporting Persons, concentration of positions in the portfolios managed by the Reporting Persons, market conditions and general economic and industry conditions, the Reporting Persons may take such actions with respect to their investment in the Issuer as they deem appropriate, including, without limitation, purchasing additional shares of the Common Stock or other financial instruments related to the Issuer or the Common Stock or selling some or all of the Common Stock, engaging in hedging or similar transactions involving securities relating to the Issuer or the Common Stock and/or otherwise changing their intention with respect to any and all matters referred to in subsections (a) through (j) of Item 4 of Schedule 13D.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The responses of each of the Reporting Persons with respect to Rows 11 and 13 of the cover pages of this Schedule 13D that relate to the aggregate number and percentage of Ordinary Shares are incorporated herein by reference.

The responses of each of the Reporting Persons with respect to Rows 7, 8, 9 and 10 of the cover pages of this Schedule 13D that relate to the number of Ordinary Shares as to which such Reporting Persons have sole or shared power to vote, or to direct the vote, and sole or shared power to dispose of, or to direct the disposition, are incorporated herein by reference.

**(b)**
See (a).

**(c)**
Except as reported in Item 3 above, the Reporting Persons have not affected any transactions in the shares of Common Stock in the sixty days prior to the date hereof.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

The Reporting Persons' responses to Items 3 - 5 are incorporated by reference into this Item 6.

All of the conversion price and share number information below gives effect to the June 2025 Reverse Split.

ASE Test Taiwan directly holds 11,777 shares of Common Stock.

On March 13, 2023, the Issuer entered into the 2023 Agreement with ASE Test Taiwan pursuant to which ASE Test Taiwan committed to pay a total aggregate amount of $2,000,000 to the Issuer in exchange for convertible promissory note(s) in three tranches in the amounts of $1,000,000 (the "First Tranche"), $500,000 (the "Second Tranche"), and $500,000 (the "Third Tranche") conditioned, among other things, on the Issuer achieving certain business milestones. ASE Test Taiwan provided $1,500,000 on as April 12, 2023 and the remaining $500,000 on September 12, 2023. The convertible note(s) issued under the 2023 Agreement were originally set to mature on March 13, 2025. On March 10, 2025, the Issuer and ASE Test Taiwan entered the 2023 Agreement Amendment, which amended and superseded the term and conversion price of the 2023 Agreement. Accordingly, ASE Test Taiwan holds a convertible note that will mature on March 12, 2027 and bears interest at the rate of 6% compounded interest per annum. At any time after the issuance and before the maturity date, the note is convertible into the Issuer's Common Stock at a conversion price equal to the lower of (a) $37.50 per share and (b) the higher of (x) the average closing price per share for the period of thirty (30) trading days prior to the day when ASE Test Taiwan exercises the conversion right or (y) $22.50 per share (or 105,868 shares), subject to anti-dilutive adjustment as set forth in the note.

On May 3, 2024, ASE Test Taiwan entered into a Convertible Note and Warrant Purchase Agreement with the Issuer (the "2024 Agreement") pursuant to which ASE Test Taiwan purchased from the Issuer a Convertible Note in the aggregate principal amount of $9,000,000. The note bears 6% compound interest and has a three-year term. The note will be convertible into shares of Common Stock at a conversion price of $22.50 per share (or 449,440 shares), subject to customary anti-dilution adjustments. As part of the 2024 Agreement, ASE Test Taiwan received a five-year common stock purchase warrant which vested and became exercisable following a six-month period from the date of issue. The warrant may be exercised for up to 100,000 shares of Common Stock at a price of $22.50 per share, customary to anti-dilution adjustments.

Effective May 3, 2024, Ainos Inc., a Cayman Islands corporation ("Ainos KY") and ASE Test Taiwan entered into a voting agreement with respect to the voting stock of the Issuer (the "Voting Agreement"). Pursuant to the Voting Agreement, ASE Test Taiwan has agreed to vote all of its current or future acquired voting stock of the Issuer in the manner determined by Ainos KY in its sole discretion. The Voting Agreement continued in effect until May 3, 2025 and was subsequently automatically renewed for an additional one-year period until May 3, 2026; thereafter, it will automatically renew for additional one-year periods unless ASE Test Taiwan provides prior notice of termination. As part of the Voting Agreement, ASE Test Taiwan agreed that, without Ainos KY's written consent, it would not sell or transfer more than 20% of its shares of the Issuer in any calendar year period through the fifth anniversary of the date of the Voting Agreement. If, in any calendar year, ASE Test Taiwan does not sell the full 20% allocation, the remaining percentage will be added to and increase the following year's allocation. The transfer restrictions will terminate upon the termination of the Voting Agreement.

Except as set forth herein, neither of the Reporting Persons has any contracts, arrangements, understandings or relationships (legal or otherwise) with any person with respect to any securities of the Issuer, including but not limited to any contracts, arrangements, understandings or relationships concerning the transfer or voting of such securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or losses, or the giving or withholding of proxies.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** ASE Technology Holding Co., Ltd.

**Signature:** /s/ Joseph Tung

**Name/Title:** Joseph Tung/ Chief Financial Officer

**Date:** 04/15/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** ASE Test, Inc.

**Signature:** /s/ Alan Li

**Name/Title:** Alan Li/ Director

**Date:** 04/15/2026